← All thesesOSCRNeutralMedium convictionTuesday 17 November 2026עברית

Oscar Health

This is the archived full research. Read the story

An American health insurer selling plans to people who buy their own cover, almost all of it paid for with federal tax credits.

Our viewNeutral Medium conviction
The scores
The profile · 1-4
Growth3/4 ↑

Revenue rose 27.5% in 2025 and 72% in Q3 2026 on share gains, but members fell 9% in the quarter, on one subsidised market.

Business quality2/4 ↑

Low running cost wins share on price, but members re-shop yearly and 2025 showed rivals' members can erase the margin.

Financial position3/4 ↑

Excess statutory capital of $994M and no debt due before 2030, but growth leans on reinsurers for about $1.1B of capital.

Execution record2/4 ↑

Estimates rose three times in 2025 and the year lost money; 2026 beat its plan twice and Q3 earned $178M, but it is one year.

Per share capture2/4 →

Shares rose 18.3% in a year after notes were swapped for stock, and the 2030 notes convert below today's price.

Potential2/4 →

The 2029 plan needs a margin never earned, share gains, and an employer market of 2.5M lives that is 0.5M today.

Risk profile2/4 →

Federal rules, court rulings on eligibility checks and a yearly payment set by CMS can each move profit in one step.

Valuation3/4 ↓

About 9.8 times earnings, 82% of a three-stage value near $39.06 at an 8% return: fair, inside the 20% margin.

Evidence quality3/4 →

Central facts are filed or CMS's, but the 2026 payment and the employer line rest on management's estimates.

The bet · 2-3 years
Safe, little upside1.0×

If it works 1.0× · if it fails you keep about 87%.

The Verdict

We rate Oscar Health Neutral. It runs cheaper than its rivals and took a large share of a shrinking market in 2026, but a federal scheme that moves money to insurers with sicker members took about a fifth of its premiums and wiped out 2025's profit, so the business is mixed. On the analysts' path the price is about 82% of our value, just short of our cushion, and that path needs a margin earned once. The deciding payment is an estimate until next June. As a bet on employer-funded plans it is defensive.

The long caseEmployers may start paying for individual plans instead of group cover, and Oscar has built the platform to sell them.

How we weighed it

The price against our value

Cuts both ways

Price at 82% of our value

The price sits just short of the margin of safety, close to the bear case.

The business

Against it

Mixed

Cheaper to run than rivals, but its profit depends on a federal transfer between insurers it cannot control.

Growth against what the price assumes

Cuts both ways

Members grew in a shrinking market, but they were won on price and re-shop every year.

What could go wrong

Against it

The transfer owed to rivals may grow again, nearly all premiums rest on federal credits and regulators may remove members.

Against competitors

Cuts both ways

Rival insurers' sicker members set its bill, which no comparison of prices captures.

How its group is behaving

Cuts both ways

It sits in none of our ranked groups; federal health policy moves it.

The latest news and report

In its favour

The profit and the raised outlook beat our test; the payment to rivals is still an estimate.

The evidence under this - 7 claims
C08facthigh confidence
Risk-adjustment transfers paid out were $1,526.4M against $10,292.1M of direct premium in 2024 (14.8%), $2,596.8M against $14,031.3M in 2025 (18.5%), and $2,314.3M against $11,696.7M in the first half of 2026 (19.8%).
against this

The first-half figure includes about $160M of favourable 2025 true-up (C11); on current-year terms an analyst on the Q2 call estimated about 17.9%.

historical · FY2024 to H1 2026written 2026-10-18
C07facthigh confidence
The 10-K says that in Q2 and Q3 2025 third-party reports showed the market's average risk scores significantly higher than expected, so Oscar raised the risk-adjustment payment it owed, and in Q4 a report showed its own members' relative scores lower than expected, so it raised it again. Centene's 10-K describes the same 2025 data from an independent actuarial firm cutting its own expected risk-adjustment revenue.
historical · 2025written 2026-10-18
C21inferencemedium confidence
Much of Oscar's 2026 growth is share taken while listed rivals priced up or pulled back, at prices that also restored its own margin.
against this
  • Share won on price in a market where members re-shop every year can be lost the same way, and Centene still has about twice Oscar's members (C19).
  • Part of the gain may be members the eligibility checks will remove (C22).
current state · 2026-06-30written 2026-10-18
C31estimatemedium confidence
Taxed and counted the way management counts its 2029 target, the 2026 guide of $850M-$950M gives $1.88 to $2.11 of profit a share, so $35.19 is 16.7 to 18.7 times 2026's profit, 17.6 at the midpoint, and 8.8 times the 2029 target of $4.00.
against this

Oscar's tax losses carried forward kept its reported tax to $38.9M over the last four quarters, so reported profit per share will be higher than this taxed figure for some years.

  1. 2026-11-05editedthe raised guide and the 4 November close
forwardwritten 2026-10-18
C32inferencemedium confidence
2026 will be Oscar's most profitable year by a wide margin; over 2024 to 2026 its operating margin averages about 0.3%, so the price is paying for a margin the company has earned once.
against this

2024 and 2025 were years of a market made sicker by Medicaid redeterminations and then a reset, which management argues will not recur (C52).

current state · 2026-09-16written 2026-10-18
C39management claimlow confidence
At Investor Day Oscar put employer-funded individual cover, which it now calls CHOICE, at under 0.2 million lives in 2023, 0.5 million or more in 2026 and 2.5 million or more by 2029. It says its own CHOICE membership about doubled in the year to February 2026, targets about three times its CHOICE market share and 10% to 15% of CHOICE in its counties by 2029, and reports about 85% retention for CHOICE members against about 75% for individual members.
against this

Oscar discloses no CHOICE member count or revenue, and its 2029 market figure rests on its own analysis of vendor data (C43).

forwardwritten 2026-10-18
C43estimatelow confidence
Oscar's CHOICE members are probably in the tens of thousands, under 1% of its 2.96 million members, which is why the line is early.
against this

The share target is stated for its counties, not nationally, so the national figure could be lower or higher; Oscar has never stated the count.

current state · 2026-09-16written 2026-10-18
01

The company

Americans who get no health cover through work or the government can buy their own plan on the exchanges the Affordable Care Act set up. Oscar sells those plans: 2,042,449 members in 18 states at the end of 2025, more than half of them in Florida.

Almost every customer pays with help, since about 97% of 2025 premiums carried a federal tax credit. Its members skew younger and healthier than the market, and it runs on its own technology, with running costs down to 14.2% of revenue in Q2 2026.

The evidence under this - 4 claims
C01facthigh confidence
Oscar sells individual and family health plans on the ACA exchanges. At the end of 2025 it had 2,042,449 members in 18 states: Florida 1,179,934, Texas 358,910 and Georgia 218,746. It had about 2,305 employees, and the 10-K names Florida, Texas and Georgia as its largest concentrations of revenue.
current state · 2025-12-31written 2026-10-18
C10management claimmedium confidence
The chief financial officer says Oscar is a risk-adjustment payer because its members skew younger, healthier and more urban than the market, more so as it grows, and that risk adjustment ran about 20% of direct premium in the first half of 2026, consistent with the full-year expectation.
against this

The same estimate rose three times in 2025 on third-party data (C07); the final figure for 2026 comes only in CMS's June 2027 report.

current state · 2026-08-06written 2026-10-18
C25facthigh confidence
The 10-K says about 97% of its members' 2025 direct premiums were subsidised by federal tax credits, 92% in 2024; the enhanced credits expired at the end of 2025, and Congress could act in 2026 to restore them.
current state · 2025-12-31written 2026-10-18
C46facthigh confidence
Running costs fell to 14.2% of revenue in Q2 2026, which the CFO called the lowest in the company's history, from 19.1% in 2024 and 17.5% in 2025. Revenue per employee rose from about $0.70M in 2021 to $5.08M in 2025 while headcount fell 4.0% in 2025 to 2,305.
against this

Part of the fall is a lower risk-adjustment share of premium and fixed costs spread over more members, both of which the CFO named; Oscar also stopped small-group plans.

historical · FY2021 to Q2 2026written 2026-10-18

How it makes money

Members, helped by their tax credits, pay a monthly premium, and Oscar keeps what is left after paying their doctors and hospitals and its own running costs. In 2025 premium was $11.47B of $11.70B of revenue; most of the rest was interest on the cash it holds. Because its members are healthier than average, Oscar must hand part of its premium to insurers with sicker members: about a fifth of it in the first half of 2026.

The evidence under this - 3 claims
C53facthigh confidence
Of 2025's $11,701.4M of revenue, premium was $11,469.9M, investment income $202.9M and other revenues $28.6M.
historical · FY2025written 2026-10-18
C08facthigh confidence
Risk-adjustment transfers paid out were $1,526.4M against $10,292.1M of direct premium in 2024 (14.8%), $2,596.8M against $14,031.3M in 2025 (18.5%), and $2,314.3M against $11,696.7M in the first half of 2026 (19.8%).
against this

The first-half figure includes about $160M of favourable 2025 true-up (C11); on current-year terms an analyst on the Q2 call estimated about 17.9%.

historical · FY2024 to H1 2026written 2026-10-18
C10management claimmedium confidence
The chief financial officer says Oscar is a risk-adjustment payer because its members skew younger, healthier and more urban than the market, more so as it grows, and that risk adjustment ran about 20% of direct premium in the first half of 2026, consistent with the full-year expectation.
against this

The same estimate rose three times in 2025 on third-party data (C07); the final figure for 2026 comes only in CMS's June 2027 report.

current state · 2026-08-06written 2026-10-18
Where the money comes from, stream by stream
StreamShare of sales (fiscal year 2025)How it earns it
Premium98.0%Health insurance premiums from members and the federal tax credit, after the risk-adjustment payment to other insurers and reinsurance.
Investment income1.7%Interest on the cash and investments held against claims and amounts owed to CMS.
Other revenues0.2%Fees from the +Oscar software, the Lucie platform and the brokerage bought in 2025.

Who runs it

Mark Bertolini, who ran Aetna from 2010 to 2018, has been chief executive since April 2023, and the company made its first profit under him. Insiders and Thrive Capital control the votes: directors and officers hold 21.8% of the shares but 77.2% of the votes.

Most of the yearly bonus rides on operating margin, premiums and running costs. Bertolini bought 1,000,000 shares from the company in April 2026 and sold about 2.45M under a plan in June; co-founder Mario Schlosser sold 750,000 outside one in August.

The evidence under this - 6 claims
C45facthigh confidence
Mark Bertolini has been chief executive since April 2023 after running Aetna from 2010 to 2018; Scott Blackley has been CFO since August 2023, and was Capital One's CFO from 2016 to 2021; co-founder Mario Schlosser ran Oscar from 2012 to April 2023 and is now President of Technology; Janet Liang, formerly of Kaiser Permanente, has run the insurance business since February 2025.
current state · 2026-04-22written 2026-10-18
C06facthigh confidence
The 10-K says 2024 was the first year since Oscar began in 2012 that it made a net profit, that it did not make one in 2025 and may not be able to do so again, and that its accumulated deficit was $3,294.4M at the end of 2025.
historical · 2012 to 2025written 2026-10-18
C33facthigh confidence
The 2026 proxy shows Thrive Capital with 14.2% of the economic interest and 68.0% of the votes, the chief executive owning 11,925,092 shares (4.5%), co-founder Mario Schlosser's Class B shares carrying 13.4% of the votes, and directors and officers together 21.8% of the economics and 77.2% of the votes.
current state · 2026-04-10written 2026-10-18
C34facthigh confidence
The proxy says the annual bonus is 80% financial measures, operating margin, direct and assumed premiums and the direct running-cost ratio, and 20% operational; 2025 paid 91% of target. 2025 share awards vest on cumulative adjusted profit with a relative-return modifier; 2026 awards vest on relative shareholder return alone, capped if absolute return is negative.
current state · 2026-04-22written 2026-10-18
C35facthigh confidence
On 6 April 2026 the chief executive bought 1,000,000 shares at $11.92 from the company in a private placement, reported on Form 4 beside the vesting of 5,733,334 performance shares and 1,000,001 withheld for tax.
against this

He sold about 2.45M shares at $28 to $30 in late June 2026 under a trading plan adopted on 10 November 2025 (C36).

historical · 2026-04-06written 2026-10-18
C36facthigh confidence
In the year to mid-October 2026 insiders made 59 open-market sales of 5,562,596 shares, 79.1% under 10b5-1 plans. The discretionary ones: Mario Schlosser sold 600,000 at $30.34 and 150,000 at $30.79 on 27 and 28 August after exercising options at $9.75, and the CFO 18,750 at $31.74 on 18 August. The chief executive's 2.45M June sales were under a plan.
against this

The insider base rate put the Q3 2026 bought-to-sold ratio at 0.78 against a 0.74 median, ordinary for this company, and most acquisitions are vesting rather than purchases.

historical · year to 2026-10-16written 2026-10-18
02

Why it wins, and who could beat it

Why customers come back

Oscar's edge is cost. The tax credit is fixed against a benchmark plan, so a plan priced below it is cheaper for the member dollar for dollar, and members compare prices every year. Running costs of 14.2% of revenue let Oscar price low and still earn.

It worked in 2026. The exchanges shrank, by management's count about 12%, yet Oscar's members grew 46.2% and its share of the counties it serves roughly doubled to about 30%. But members won on price leave on price.

The evidence under this - 5 claims
C04facthigh confidence
Oscar had 2,691,885 members at 30 September 2026 against 2,116,904 a year earlier, up 27.2%, and 2,963,002 at 30 June, so 271,117 left in the quarter. The count includes members enrolled through an employer's ICHRA, which the release does not split out; it does not say how much of the fall is retroactive removals (C22).
against this

The 10-Q expects 250,000 to 300,000 of these members to be removed retroactively under eligibility rules (C22), so the year-end count will be lower.

  1. 2026-11-05editedQ3 release gives members at 30 September
current state · 2026-09-30written 2026-10-18
C17management claimmedium confidence
Management says total exchange enrolment is 19.2 million, down 12% from a year earlier, and that Oscar's paid members grew about 60% between 1 February 2025 and 1 February 2026 while the market fell about 13%.
against this

CMS's own snapshot counts 22,973,219 selected plans (C16); fewer pay, but the 19.2 million is management's figure rather than a CMS table read here.

current state · 2026-08-06written 2026-10-18
C18management claimmedium confidence
Management puts Oscar's share of the counties it serves at about 16% after the 2024 open enrolment and about 30% after 2026's, and lists competitor exits among the 2025 market changes it priced against.
against this

Nationally its 2,963,002 members are 12.9% of plan selections (C16, C04); the in-county share is the company's own calculation.

current state · 2026-09-16written 2026-10-18
C21inferencemedium confidence
Much of Oscar's 2026 growth is share taken while listed rivals priced up or pulled back, at prices that also restored its own margin.
against this
  • Share won on price in a market where members re-shop every year can be lost the same way, and Centene still has about twice Oscar's members (C19).
  • Part of the gain may be members the eligibility checks will remove (C22).
current state · 2026-06-30written 2026-10-18
C46facthigh confidence
Running costs fell to 14.2% of revenue in Q2 2026, which the CFO called the lowest in the company's history, from 19.1% in 2024 and 17.5% in 2025. Revenue per employee rose from about $0.70M in 2021 to $5.08M in 2025 while headcount fell 4.0% in 2025 to 2,305.
against this

Part of the fall is a lower risk-adjustment share of premium and fixed costs spread over more members, both of which the CFO named; Oscar also stopped small-group plans.

historical · FY2021 to Q2 2026written 2026-10-18

The threat

Its biggest rivals are Centene, the largest exchange insurer with 5.5 million members, and the local Blue Cross plans. In Florida, Oscar's largest state, Florida Blue received $1.32B from the risk-adjustment scheme for 2025 while Oscar's Florida insurer paid $1.47B: a rival with sicker members is paid partly out of Oscar's premiums.

The evidence under this - 3 claims
C19facthigh confidence
Centene's 10-K says it is the largest exchange insurer, with 5.5 million members in 29 states at the end of 2025; that 2025 independent actuarial data showed a sicker exchange pool than expected and cut its risk-adjustment revenue; and that it repriced for 2026 in states covering 95% of its exchange members. Its Commercial segment, mostly exchange plans, had $42,003M of $194,777M of 2025 revenue.
current state · 2025-12-31written 2026-10-18
C09facthigh confidence
CMS's risk adjustment report for 2025 shows Oscar Insurance Company of Florida paying $1,466,455,725.41 in the individual market, Oscar's Texas insurer $535,020,864.77 and its Georgia insurer $270,684,882.51, while Blue Cross and Blue Shield of Florida received $1,323,888,872.22. Transfers were 11.0% of premiums across the individual market.
historical · benefit year 2025written 2026-10-18
C51facthigh confidence
The 10-K names its principal individual-market competitors only as classes: national carriers, regional carriers, Medicaid-focused insurers selling exchange plans, and local Blue Cross plans; some have greater resources and broader networks.
current state · 2025-12-31written 2026-10-18

The rivals: CNC, ELV, UNH, MOH, and 1 more that is private, in-house or listed abroad.

Who else does this, rival by rival
TickerRivalWhere it competesHow far alongPriced against it
CNCCentene Corporation (Ambetter Health)Priced against it: Same productOscar's ACA individual plansOn saleSame product
PrivateFlorida BluePriced against it: PrivateOscar's ACA individual plansOn salePrivate
ELVElevance Health's Blue plansPriced against it: One segment onlyOscar's ACA individual plansOn saleOne segment only
UNHGroup health plans from the large insurers, such as UnitedHealth'sPriced against it: One segment onlyOscar CHOICE and the +Oscar platformsOn saleOne segment only
MOHMolina HealthcarePriced against it: One segment only-On saleOne segment only
03

How big it could get

How big this could get

The exchanges had 22,973,219 plan selections for 2026. At the roughly $7,900 a year Oscar collects per member, that is a market of about $181B, and Oscar's 2,963,002 members are 12.9% of it. Nobody yet measures how large the part employers pay for will grow, and this count leaves it out.

The evidence under this - 3 claims
C16facthigh confidence
CMS reports 22,973,219 plan selections on the exchanges for 2026, 3,382,189 of them new consumers; Florida 4,538,772, Texas 4,172,233 and Georgia 1,301,254.
current state · 2026-01-15written 2026-10-18
C47estimatemedium confidence
Oscar collects about $7,900 of direct premium per member-year, and at that price the exchange market is about $181B a year; Oscar's 2,963,002 members are 12.9% of 2026's plan selections.
against this

Not every selected plan is paid for, and Oscar's members are younger than average, so the market average premium may differ from Oscar's.

current state · 2026-06-30written 2026-10-18
C04facthigh confidence
Oscar had 2,691,885 members at 30 September 2026 against 2,116,904 a year earlier, up 27.2%, and 2,963,002 at 30 June, so 271,117 left in the quarter. The count includes members enrolled through an employer's ICHRA, which the release does not split out; it does not say how much of the fall is retroactive removals (C22).
against this

The 10-Q expects 250,000 to 300,000 of these members to be removed retroactively under eligibility rules (C22), so the year-end count will be lower.

  1. 2026-11-05editedQ3 release gives members at 30 September
current state · 2026-09-30written 2026-10-18
04

The results

The numbers

Is it growing?Fast

Sales grew 55% over the twelve months to Sep 2026, faster than the 28% in the year to Dec 2025.

Dec 2021: $1.84BDec 2022: $3.96BDec 2023: $5.86BDec 2024: $9.18BDec 2025: $11.7B12 mo to Sep 2026: $17.5B$1.84B$17.5B
Is it profitable?Thin

Operating margin is 5.4%, up from −4.0% in the year to Dec 2023.

Dec 2021: −30%Dec 2022: −15%Dec 2023: −4.0%Dec 2024: 0.6%Dec 2025: −3.4%12 mo to Sep 2026: 5.4%−30%5.4%
How steady is it?Swingy

Yearly sales growth has ranged from +28% to +297% over the last 5 years.

Dec 2021: +297%Dec 2022: +116%Dec 2023: +48%Dec 2024: +57%Dec 2025: +28%+297%+28%
Does it earn good returns?Strong

Each dollar put into the business earns 41% a year after tax, up from 3.7% in the year to Dec 2024.

Dec 2024: 3.7%12 mo to Sep 2026: 41%3.7%41%
Is it making cash?Strong

It turned 24% of sales into free cash, $4.14B over the last twelve months.

Dec 2021: −$208MDec 2022: $351MDec 2023: −$298MDec 2024: $950MDec 2025: $1.06B12 mo to Sep 2026: $4.14B−$208M$4.14B
Is the balance sheet safe?Net cash

It holds $7.49B of cash against $432M of debt, $7.06B more cash than it owes.

Dec 2021: $1.69BDec 2022: $2.66BDec 2023: $2.26BDec 2024: $1.85BDec 2025: $3.56B12 mo to Sep 2026: $7.06B$1.69B$7.06B
Are shares being diluted?Diluting

The share count rose 94% in 4.8 years, and pay in shares costs 0.4% of sales.

Dec 2021: 179MDec 2022: 212MDec 2023: 222MDec 2024: 266MDec 2025: 262M12 mo to Sep 2026: 346M179M346M
All the numbers

Filed figures from the company's 10-K and 10-Q, read 2026-11-10. Fiscal years end in December.

Dec 2021Dec 2022Dec 2023Dec 2024Dec 202512 mo to Sep 2026
Size and growth
Sales$1.84B$3.96B$5.86B$9.18B$11.7B$17.5B
Sales growth+297%+116%+48%+57%+28%+55%
Profit
Operating margin−30%−15%−4.0%0.6%−3.4%5.4%
Net margin−31%−15%−4.6%0.3%−3.8%4.9%
What growth costs, per sales dollar
General and admin14%0.4%0.5%0.4%0.2%0.2%
Pay in shares4.7%2.8%2.7%1.2%0.7%0.4%
Capital spending1.4%0.7%0.4%0.3%0.3%0.2%
Cash
Cash from operations−$182M$380M−$272M$978M$1.09B$4.18B
Free cash flow−$208M$351M−$298M$950M$1.06B$4.14B
Balance sheet
Cash and short-term investments$1.69B$2.96B$2.56B$2.15B$3.99B$7.49B
Debt$0$298M$299M$300M$430M$432M
Net cash$1.69B$2.66B$2.26B$1.85B$3.56B$7.06B
Returns and shares
Return on capital---3.7%-41%
Shares (diluted)179M212M222M266M262M346M

What growth costs

For an insurer, growth costs running expenses and broker commissions, and here growing has made each member cheaper to serve: running costs fell as a share of revenue each year while revenue rose. The swings in profit come from claims and the risk-adjustment payment, not from what growth costs.

The evidence under this - 3 claims
C05facthigh confidence
2025 revenue was $11,701.4M against $9,177.6M in 2024. Profit from operations was a loss of $396.4M against a profit of $57.3M, net income a loss of $443.2M against a profit of $25.4M, the medical loss ratio 87.4% against 81.7% and running costs 17.5% of revenue against 19.1%. The operating margin was minus 3.4% against 0.6%.
historical · FY2025 and FY2024written 2026-10-18
C02facthigh confidence
Q2 2026 revenue was $4,880.2M against $2,863.9M in Q2 2025. The medical loss ratio, claims as a share of premium, was 79.2% against 91.1%; running costs were 14.2% of revenue against 18.7%. Profit from operations was $388.6M against a loss of $230.5M; net income $361.8M, or $1.10 a diluted share.
historical · Q2 2026written 2026-10-18
C46facthigh confidence
Running costs fell to 14.2% of revenue in Q2 2026, which the CFO called the lowest in the company's history, from 19.1% in 2024 and 17.5% in 2025. Revenue per employee rose from about $0.70M in 2021 to $5.08M in 2025 while headcount fell 4.0% in 2025 to 2,305.
against this

Part of the fall is a lower risk-adjustment share of premium and fixed costs spread over more members, both of which the CFO named; Oscar also stopped small-group plans.

historical · FY2021 to Q2 2026written 2026-10-18

The last report (5 Nov)

Quarter ended September 2026, filed figures.

72%
Sales growth
against the same quarter a year earlier
5.3%
Growth from the quarter before
against 5.0% the quarter before that
3¢
Operating profit
per dollar of sales

Q3 2026 revenue rose 72% to $5.1B and Oscar earned $178.0M from operations, against a $129.3M loss a year earlier. Claims took 84.0% of premium against 88.5%, running costs fell to 14.0% of revenue, and profit was $0.49 a share where analysts expected a loss. It raised its 2026 forecast for operating profit to $850M-$950M from $600M-$800M.

About $250M of the quarter's revenue was a better estimate of what Oscar owes rivals under the federal scheme, an estimate the government settles only in June 2027. Members fell to 2.69M from 2.96M in June, and the report does not say how many were removed.

What it did to the thesisThe profit and the raise beat the test we set, and a better estimate of the payment to rivals supports the case. It is still an estimate, so the view stays Neutral.

The quarter in detail

Sales growth from the previous quarter, filed figures.

Earnings per share $0.49 against $-0.14 expected.

The evidence under this - 5 claims
C57facthigh confidence
Q3 2026 revenue rose 72% to $5,139.3M, including a $250M benefit from updated risk adjustment estimates; the medical loss ratio was 84.0% against 88.5%, with $42M of favourable prior-period development against $84M; running costs were 14.0% of revenue; profit from operations was $178.0M against a loss of $129.3M, and net income $167.3M, or $0.49 a diluted share. For nine months profit from operations was $1,270.7M.
historical · Q3 2026written 2026-11-05
C58management claimmedium confidence
On 5 November 2026 Oscar raised its 2026 guide for profit from operations to $850M-$950M from $600M-$800M, revenue to $19.0B-$19.3B, and cut its medical loss ratio guide to 80.5%-81.5% and its running-cost guide to 15.1%-15.6%. With $1,270.7M earned in nine months, the guide implies a fourth-quarter loss of $320.7M to $420.7M, against $333.8M in Q4 2025.
against this

About $250M of Q3 revenue is an updated risk adjustment estimate (C57), which CMS settles only in its June 2027 report (C08), and the release does not say how much of the raise is claims.

forwardwritten 2026-11-05
C11management claimmedium confidence
Q2 2026 included $164M of favourable development on earlier periods, $232M in the first half, most of it about $160M from CMS's final 2025 risk-adjustment report. The chief financial officer says the Q2 medical loss ratio excluding it was about 82%.
against this

An analyst on the call computed about 85.2% for Q2 excluding the releases and the true-up; the CFO said the two would reconcile after the call.

historical · Q2 2026written 2026-10-18
C13estimatehigh confidence
The 2026 guide now implies the second half loses $142.7M to $242.7M from operations, against a loss of $463.0M in the second half of 2025, on revenue of about $9.5B to $9.8B rather than $5.8B; Q3 earned $178.0M, so the fourth quarter carries the whole loss.
against this

Second halves lose money at every ACA insurer as members meet their deductibles, and management says it has not taken full credit for favourable morbidity data (C52).

  1. 2026-11-05editedthe raised guide and Q3 profit shrank the implied second-half loss
forwardwritten 2026-10-18
C04facthigh confidence
Oscar had 2,691,885 members at 30 September 2026 against 2,116,904 a year earlier, up 27.2%, and 2,963,002 at 30 June, so 271,117 left in the quarter. The count includes members enrolled through an employer's ICHRA, which the release does not split out; it does not say how much of the fall is retroactive removals (C22).
against this

The 10-Q expects 250,000 to 300,000 of these members to be removed retroactively under eligibility rules (C22), so the year-end count will be lower.

  1. 2026-11-05editedQ3 release gives members at 30 September
current state · 2026-09-30written 2026-10-18
What management did with the money

Oscar put $425.5M into its insurers in the first half of 2026 to back growth, $300M of it into a new Florida HMO. Its debt is $410M of convertible notes due 2030. Swapping other notes for about 30.8M shares in 2025 is part of why the share count rose 18.3% in a year.

Insiders in 2026Q3: 18 purchases and 23 sales, from their Form 4 filings.

The evidence under this - 3 claims
C26facthigh confidence
The insurance subsidiaries held about $1.9B of statutory capital at 30 June 2026, about $994M above the minimum against $356M at the end of 2025. The parent contributed $425.5M in the half, $300M of it to a new Florida HMO. Without quota-share reinsurance they would need about $1.1B more capital.
current state · 2026-06-30written 2026-10-18
C28facthigh confidence
Oscar owes $410M of 2.25% convertible notes due 2030, convertible at about $24.82 a share with a capped call to $37.46, and $35M of 7.25% notes due 2031 convertible at about $8.32. In November 2025 Dragoneer exchanged $250M of the 2031 notes for about 30.1M shares plus about 0.7M more as an inducement.
current state · 2026-06-30written 2026-10-18
C29facthigh confidence
Weighted basic shares were 302.2M in Q2 2026 against 255.5M in Q2 2025, up 18.3%; diluted shares were 333.4M. Outstanding shares on the 10-Q cover were 273.4M Class A and 35.2M Class B.
historical · Q2 2025 and Q2 2026written 2026-10-18
05

The price, and where we disagree

In short. Fair. The price is about 82% of what we think the business is worth, at an 8% yearly return.

Share price
$35.19
close,
Price for each $1 of yearly profit
18.6
its 6-year normal -5.0

The shares doubled in six months from $15.79 in April, almost all of it a higher price per dollar of sales, and closed at $35.19 on 4 November, after the report.

The tests continue. The 10-Q and call, due soon, should show how many members CMS removed and the payment's share of premium. The 2027 sign-up season runs from 1 November to 15 January, and CMS's June 2027 report settles 2026's risk-adjustment bill.

The evidence under this - 5 claims
C30facthigh confidence
The shares closed at $31.89 on 16 October 2026 and $35.19 on 4 November, 10.3% higher; the 52-week range at 16 October was $10.69 to $35.01. At $35.19 they trade at 14.5 times trailing profit per share of $2.42 (minus $1.24, $2.07, $1.10 and $0.49 for the last four quarters). Short interest was 6.49% of the float at the 30 September settlement.
  1. 2026-11-05editedre-struck at the 4 November close on trailing profit with Q3
current state · 2026-11-04written 2026-10-18
C56facthigh confidence
Oscar lost $1.24 a share in Q4 2025 against $0.92 expected, reported 10 February 2026, then earned $2.07 a share in Q1 2026 against $1.21 expected; the shares were $15.79 on 17 April 2026.
historical · Q4 2025 and Q1 2026written 2026-10-18
C22facthigh confidence
The 10-Q says that as of 1 July 2026 about 250,000 to 300,000 members were expected to be retroactively disenrolled under CMS program integrity rules or fraud, waste and abuse law, and that premium for them is recorded as owed back to CMS rather than as revenue.
current state · 2026-07-01written 2026-10-18
C23facthigh confidence
The 10-Q says a federal court nullified parts of CMS's 2025 Program Integrity Rules on 12 June 2026, that the 2027 payment notice finalised on 15 May 2026 reintroduced stricter income checks, and that a court stayed those on 16 July 2026, so 2027's open enrolment runs 1 November to 15 January under mostly the old rules.
current state · 2026-07-20written 2026-10-18
C24management claimmedium confidence
The chief executive expects second-half membership churn about twice the 1% to 2% a month assumed earlier, as CMS eligibility removals delayed from Q2 arrive, and says the effects are in the guide. An analyst said CMS had sent insurers a list of 1 million members possibly unauthorised, about 80% in Florida and Texas; management gave no Oscar figure.
against this

The 10-Q states 250,000 to 300,000 expected removals (C22), but the CMS list Oscar is reviewing was not quantified for Oscar.

forwardwritten 2026-10-18
The betSafe, little upside
If it works
1.0×
from today's value, at the stated multiple
If it fails
keep 87%
of today's market value: the rest of the company, less its debt
How we value it
Method
Cash the business will produce, in three stages
Required return
8%
Long-run growth
4%
Moat
No moat
BearBaseBull
Sales growth, years 1 to 316.1%, 16.1%, 28.5%16.1%, 16.1%, 28.5%20.1%, 20.1%, 35.6%
Normal operating margin2.8%3.5%3.8%
Return on new capital after year ten8%8%11%
Value a share$28.35$39.06$57.93
Price
$32.14
Priced on
9 Nov
Price as a share of the base value
82%
Yearly return the price offers on the base case
9.3%

Where each figure comes from

FigureSourceWhere exactly
Sales, the last twelve monthsFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 5 Nov 2026; the four quarters to that date.
Operating margin todayFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 5 Nov 2026; the four quarters to that date.
Tax rateOur method's ruleThe full normal rate, since past losses hold the filed rate low only until they are used up.
Sales per dollar of new capitalOur method's ruleOur default of 2, since the filings give no operating capital to read.
SharesData vendorFMP's count of listed shares, since the filed diluted count is on another basis (a split since, a second class or a depositary ratio).
Cash and investmentsFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 5 Nov 2026; the balance sheet on that date.
DebtFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 5 Nov 2026; the balance sheet on that date.
Sales growth, years 1 to 3Analysts' forecastsFMP's consensus for the years to 31 Dec 2026, 31 Dec 2027 and 31 Dec 2028, as it stood when the value was struck on 10 Nov 2026: the average of 4 to 9 analysts' revenue estimates, 16.1%, 16.1%, 28.5%. FMP publishes how many analysts, not who they are.
Normal operating marginAnalysts' forecastsFMP's consensus operating margin for the year to 31 Dec 2028, the average of 9 analysts' estimates, 4.1%, less stock pay of 0.4% of sales. FMP publishes how many analysts, not who they are.
Return on new capital after year tenOur method's ruleSet by our reading of the moat: the 8% rate with none, 12% with an average one, 15% with a strong one; the bear case earns the rate.
The bear and bull casesOur judgementOur reading of the evidence; each case below names it.
PriceMarket priceFMP's closing price on 9 Nov 2026.

What each case rests on

Bear caseGrowth follows the analysts' path, the margin settles a fifth lower at 2.8%, and new capital earns only the 8% rate: the downturn test. At this margin an added dollar of sales earns less than the rate on the capital it needs, so slower growth would be worth more; the test keeps the growth.

Base caseRevenue grows 16%, 16% and 28% over three years, the analysts' path (C59), then fades toward 4%, closing 30% of the gap each year; the margin moves to 3.5%, the analysts' year-three figure after stock pay; tax is 25%, the federal 21% plus state tax, the full rate once past losses are used up.

Bull caseGrowth runs a quarter above the analysts' path, 20%, 20% and 36%, the margin reaches 3.8%, and new capital earns 11%.

What moves the base value

LowerHigher
Growth in years 1 to 3, a quarter lower or higher$42.99$34.28
The normal margin, 15% lower or higher$31.03$47.10
Capital per dollar of growth, a quarter more or less$22.96$48.73
Return on new capital after year ten, at the rate or one step up$39.06$51.73
The rate, a point higher or lower$29.52$55.99
Long-run growth a point lower$39.06-

Value a share as growth and margin change

Normal margin ↓ · growth →50%75%100%125%150%
2.8%$39.38$34.40$28.35$21.01$12.17
3.2%$42.80$38.70$33.70$27.64$20.33
3.5%$46.21$42.99$39.06$34.28$28.49
3.9%$49.63$47.29$44.42$40.91$36.64
4.2%$53.04$51.58$49.78$47.55$44.80

Growth is shown as a share of the base case's. Green: the price is at or under 80% of that value. Red: at or over 120%.

How we read the multiple

Fully taxed, Oscar's 2026 guide gives about $2.00 of profit a share, so a buyer at $35.19 pays about 18 times this year's profit. That would be ordinary for a steady insurer, and Oscar is not yet one: over 2024 to 2026 its operating margin averages about 0.3%, and 2026 is the only year with a real margin.

If it reaches management's 2029 target of $4.00 a share, today's price is 9 times that, which is why the shares are not dear either.

Against its own history. Oscar has rarely had a profit to price, so its own past says little about what buyers should pay for each dollar of it.

The evidence under this - 4 claims
C31estimatemedium confidence
Taxed and counted the way management counts its 2029 target, the 2026 guide of $850M-$950M gives $1.88 to $2.11 of profit a share, so $35.19 is 16.7 to 18.7 times 2026's profit, 17.6 at the midpoint, and 8.8 times the 2029 target of $4.00.
against this

Oscar's tax losses carried forward kept its reported tax to $38.9M over the last four quarters, so reported profit per share will be higher than this taxed figure for some years.

  1. 2026-11-05editedthe raised guide and the 4 November close
forwardwritten 2026-10-18
C32inferencemedium confidence
2026 will be Oscar's most profitable year by a wide margin; over 2024 to 2026 its operating margin averages about 0.3%, so the price is paying for a margin the company has earned once.
against this

2024 and 2025 were years of a market made sicker by Medicaid redeterminations and then a reset, which management argues will not recur (C52).

current state · 2026-09-16written 2026-10-18
C14management claimlow confidence
Oscar's 2029 targets are revenue growth above 20% a year, an operating margin of 5% to 7% and profit of $4.00 or more a share, assuming about $20M of interest and other costs, a tax rate in the mid-20s and 331M diluted shares growing 2% to 3% a year; also an 80% medical loss ratio, running costs under 15% and 18% or more of the national market.
against this

Oscar's best year before 2026 earned 0.6% (C05, C32), and its 2024 Investor Day targets were followed by a 2025 loss (C15).

forwardwritten 2026-10-18
C30facthigh confidence
The shares closed at $31.89 on 16 October 2026 and $35.19 on 4 November, 10.3% higher; the 52-week range at 16 October was $10.69 to $35.01. At $35.19 they trade at 14.5 times trailing profit per share of $2.42 (minus $1.24, $2.07, $1.10 and $0.49 for the last four quarters). Short interest was 6.49% of the float at the 30 September settlement.
  1. 2026-11-05editedre-struck at the 4 November close on trailing profit with Q3
current state · 2026-11-04written 2026-10-18
Priced against its rivals

Only Centene sells the same thing to the same buyers as a large part of what it does. A price comparison needs at least two, so the price is judged against its own history instead.

Private or foreign rivals that cannot be priced: Florida Blue (GuideWell Mutual Holding Corporation), Health Care Service Corporation (Blue Cross and Blue Shield of Texas).

The bet: what it pays if it works

The bet is that employers stop buying group cover and instead give workers money to buy their own plans, and that Oscar, which bought the platforms to sell them, wins a large slice. Management expects that market to grow several times over by 2029.

Even at the share Oscar targets, the profit is small beside the rest of the company, so success would move the price little. If it fails, shareholders keep most of what they own, because the exchange plans carry the value.

Oscar CHOICE and the +Oscar platforms earnings in two to three yearsCHOICE members neededAt the stated multiple
$75.00Mabout 250.0K at 100% kept1.0×
$112.50M (the big win)about 375.0K at 100% kept1.0×
$225.00Mabout 750.0K at 100% kept1.2×

To pay 2× (a Fair bet) it would need about $860.64M of Oscar CHOICE and the +Oscar platforms earnings (about 2.9M CHOICE members); to pay 5× (a Cheap bet), about $3.14B of Oscar CHOICE and the +Oscar platforms earnings (about 10.5M CHOICE members), at the same multiple.

Each row is Oscar CHOICE and the +Oscar platforms alone, plus the rest of the company (Oscar's ACA individual plans) counted at about $7.92B.

The steps it has to take

  • Done Enrolment platform bought and rivals signed onto ICHRAx
  • Done Oscar CHOICE membership doubles in a year
  • In progress 250 or more off-exchange products for the 2027 open enrolment due 2026-11
  • Not started Oscar discloses its CHOICE members or revenue due 2027-02
  • Not started 10% to 15% of CHOICE in its counties due 2029-12
The detail behind the label
Rating
Expensive
the big win's payoff against the 2× and 5× lines
Cheap bet at about
$7.15
80% below the price (close, )
The option
1.1×
what Oscar CHOICE and the +Oscar platforms is worth if it works, against what the price pays for it
The evidence under this - 6 claims
C39management claimlow confidence
At Investor Day Oscar put employer-funded individual cover, which it now calls CHOICE, at under 0.2 million lives in 2023, 0.5 million or more in 2026 and 2.5 million or more by 2029. It says its own CHOICE membership about doubled in the year to February 2026, targets about three times its CHOICE market share and 10% to 15% of CHOICE in its counties by 2029, and reports about 85% retention for CHOICE members against about 75% for individual members.
against this

Oscar discloses no CHOICE member count or revenue, and its 2029 market figure rests on its own analysis of vendor data (C43).

forwardwritten 2026-10-18
C40factmedium confidence
The HRA Council's 2026 report, built from 17 member platforms' enrolment records, says ICHRA-covered lives passed 500,000 at the start of 2026, that more than 20,000 businesses offer ICHRA or QSEHRA, and that adoption among large employers more than doubled on average.
against this

The HRA Council is a trade body of the platforms that sell ICHRA, so its count is an interested party's, though built from records rather than surveys.

current state · 2026-01-31written 2026-10-18
C43estimatelow confidence
Oscar's CHOICE members are probably in the tens of thousands, under 1% of its 2.96 million members, which is why the line is early.
against this

The share target is stated for its counties, not nationally, so the national figure could be lower or higher; Oscar has never stated the count.

current state · 2026-09-16written 2026-10-18
C44estimatelow confidence
A CHOICE member earning management's 2029 margin would make Oscar about $300 of profit a year, and about $150 at half that margin.
against this

CHOICE members choose silver and gold more often (C40), which carry higher premiums, but Oscar has published no margin for the line.

forwardwritten 2026-10-18
C41management claimlow confidence
The chief executive says ICHRAx, an enrolment platform built on the federally approved direct-enrolment system Oscar bought, has all its competitors on it, that its plan-selection tools can save employers as much as 26% of their cost, and that Allstate Health and Aflac are among partners on its Lucie marketplace; he says the employer conversion fees are not regulated like premium and carry higher margins.
against this

Other revenues, where platform fees would sit, were $28.6M in all of 2025 (C53), and no ICHRAx figure has been published.

current state · 2026-08-06written 2026-10-18
C42facthigh confidence
In May 2025 Oscar bought Lucie, a direct-enrolment platform the 10-K calls one of only 11 CMS-approved solutions, an individual-market brokerage and Healthinsurance.org, to power ICHRA; its +Oscar Campaign Builder sells engagement software to providers and payers.
historical · 2025written 2026-10-18

Where we disagree with the market

The market believes

2026 is a cycle top: the shares doubled, most analysts rate them hold or sell, and a second-half loss was expected.

We believe

The year's margin turns less on claims than on the risk-adjustment payment, set by rivals' members and settled a year late, so the shares are fair, not cheap.

The payment is published once a year, in CMS's June report, and every quarterly figure until then is an estimate. 2025's loss arrived exactly that way, at Centene as well as Oscar, when outside data showed the market sicker than expected.

We would be wrong if CMS's June 2027 report puts Oscar's 2026 payment at or below 20% of premium, with members above 2.6 million after removals. Then 2026's margin would look repeatable, and 18 times its profit would look low.

What analysts say, and the evidence
Analysts positive
27%
of 11, 1 Oct
Four months earlier
23%
of 13, 1 Jun
The evidence under this - 7 claims
C08facthigh confidence
Risk-adjustment transfers paid out were $1,526.4M against $10,292.1M of direct premium in 2024 (14.8%), $2,596.8M against $14,031.3M in 2025 (18.5%), and $2,314.3M against $11,696.7M in the first half of 2026 (19.8%).
against this

The first-half figure includes about $160M of favourable 2025 true-up (C11); on current-year terms an analyst on the Q2 call estimated about 17.9%.

historical · FY2024 to H1 2026written 2026-10-18
C09facthigh confidence
CMS's risk adjustment report for 2025 shows Oscar Insurance Company of Florida paying $1,466,455,725.41 in the individual market, Oscar's Texas insurer $535,020,864.77 and its Georgia insurer $270,684,882.51, while Blue Cross and Blue Shield of Florida received $1,323,888,872.22. Transfers were 11.0% of premiums across the individual market.
historical · benefit year 2025written 2026-10-18
C07facthigh confidence
The 10-K says that in Q2 and Q3 2025 third-party reports showed the market's average risk scores significantly higher than expected, so Oscar raised the risk-adjustment payment it owed, and in Q4 a report showed its own members' relative scores lower than expected, so it raised it again. Centene's 10-K describes the same 2025 data from an independent actuarial firm cutting its own expected risk-adjustment revenue.
historical · 2025written 2026-10-18
C19facthigh confidence
Centene's 10-K says it is the largest exchange insurer, with 5.5 million members in 29 states at the end of 2025; that 2025 independent actuarial data showed a sicker exchange pool than expected and cut its risk-adjustment revenue; and that it repriced for 2026 in states covering 95% of its exchange members. Its Commercial segment, mostly exchange plans, had $42,003M of $194,777M of 2025 revenue.
current state · 2025-12-31written 2026-10-18
C10management claimmedium confidence
The chief financial officer says Oscar is a risk-adjustment payer because its members skew younger, healthier and more urban than the market, more so as it grows, and that risk adjustment ran about 20% of direct premium in the first half of 2026, consistent with the full-year expectation.
against this

The same estimate rose three times in 2025 on third-party data (C07); the final figure for 2026 comes only in CMS's June 2027 report.

current state · 2026-08-06written 2026-10-18
C30facthigh confidence
The shares closed at $31.89 on 16 October 2026 and $35.19 on 4 November, 10.3% higher; the 52-week range at 16 October was $10.69 to $35.01. At $35.19 they trade at 14.5 times trailing profit per share of $2.42 (minus $1.24, $2.07, $1.10 and $0.49 for the last four quarters). Short interest was 6.49% of the float at the 30 September settlement.
  1. 2026-11-05editedre-struck at the 4 November close on trailing profit with Q3
current state · 2026-11-04written 2026-10-18
C31estimatemedium confidence
Taxed and counted the way management counts its 2029 target, the 2026 guide of $850M-$950M gives $1.88 to $2.11 of profit a share, so $35.19 is 16.7 to 18.7 times 2026's profit, 17.6 at the midpoint, and 8.8 times the 2029 target of $4.00.
against this

Oscar's tax losses carried forward kept its reported tax to $38.9M over the last four quarters, so reported profit per share will be higher than this taxed figure for some years.

  1. 2026-11-05editedthe raised guide and the 4 November close
forwardwritten 2026-10-18
06

What could go wrong, and how we would know

The risks

  • Rivals' members set the bill. If rivals' members prove sicker than Oscar's again, the risk-adjustment payment rises, as in 2025, when it helped turn a profit into a $396.4M loss.
  • The subsidy is the product. About 97% of premiums carried a federal tax credit. The enhanced credits expired after 2025, and any further cut shrinks the market Oscar sells into.
  • Members removed after the fact. CMS eligibility checks are expected to remove 250,000 to 300,000 members retroactively, and their premium is owed back rather than kept.
  • Members won on price leave. Oscar won 2026's members by being cheap, and members re-shop every year, so a rival pricing lower for 2027 can take them back.
  • Profit leans on old estimates. $232M of first-half profit was earlier years' estimates reversing, and the guide still implies a second-half loss of $142.7M to $242.7M.
  • Insiders hold the votes. Thrive Capital and the founders control most of the votes through 20-vote shares, so outside holders cannot change the board.
The evidence under this - 9 claims
C07facthigh confidence
The 10-K says that in Q2 and Q3 2025 third-party reports showed the market's average risk scores significantly higher than expected, so Oscar raised the risk-adjustment payment it owed, and in Q4 a report showed its own members' relative scores lower than expected, so it raised it again. Centene's 10-K describes the same 2025 data from an independent actuarial firm cutting its own expected risk-adjustment revenue.
historical · 2025written 2026-10-18
C05facthigh confidence
2025 revenue was $11,701.4M against $9,177.6M in 2024. Profit from operations was a loss of $396.4M against a profit of $57.3M, net income a loss of $443.2M against a profit of $25.4M, the medical loss ratio 87.4% against 81.7% and running costs 17.5% of revenue against 19.1%. The operating margin was minus 3.4% against 0.6%.
historical · FY2025 and FY2024written 2026-10-18
C25facthigh confidence
The 10-K says about 97% of its members' 2025 direct premiums were subsidised by federal tax credits, 92% in 2024; the enhanced credits expired at the end of 2025, and Congress could act in 2026 to restore them.
current state · 2025-12-31written 2026-10-18
C22facthigh confidence
The 10-Q says that as of 1 July 2026 about 250,000 to 300,000 members were expected to be retroactively disenrolled under CMS program integrity rules or fraud, waste and abuse law, and that premium for them is recorded as owed back to CMS rather than as revenue.
current state · 2026-07-01written 2026-10-18
C21inferencemedium confidence
Much of Oscar's 2026 growth is share taken while listed rivals priced up or pulled back, at prices that also restored its own margin.
against this
  • Share won on price in a market where members re-shop every year can be lost the same way, and Centene still has about twice Oscar's members (C19).
  • Part of the gain may be members the eligibility checks will remove (C22).
current state · 2026-06-30written 2026-10-18
C11management claimmedium confidence
Q2 2026 included $164M of favourable development on earlier periods, $232M in the first half, most of it about $160M from CMS's final 2025 risk-adjustment report. The chief financial officer says the Q2 medical loss ratio excluding it was about 82%.
against this

An analyst on the call computed about 85.2% for Q2 excluding the releases and the true-up; the CFO said the two would reconcile after the call.

historical · Q2 2026written 2026-10-18
C13estimatehigh confidence
The 2026 guide now implies the second half loses $142.7M to $242.7M from operations, against a loss of $463.0M in the second half of 2025, on revenue of about $9.5B to $9.8B rather than $5.8B; Q3 earned $178.0M, so the fourth quarter carries the whole loss.
against this

Second halves lose money at every ACA insurer as members meet their deductibles, and management says it has not taken full credit for favourable morbidity data (C52).

  1. 2026-11-05editedthe raised guide and Q3 profit shrank the implied second-half loss
forwardwritten 2026-10-18
C33facthigh confidence
The 2026 proxy shows Thrive Capital with 14.2% of the economic interest and 68.0% of the votes, the chief executive owning 11,925,092 shares (4.5%), co-founder Mario Schlosser's Class B shares carrying 13.4% of the votes, and directors and officers together 21.8% of the economics and 77.2% of the votes.
current state · 2026-04-10written 2026-10-18
C37facthigh confidence
Thrive Capital's amended 13D of 18 September 2026 reports about 6.34M Class A shares distributed in kind to its fund partners and Joshua Kushner beneficially owning 37,525,451 shares, 12.1%. Class B shares carry 20 votes each and convert to Class A automatically seven years after the 2021 listing.
current state · 2026-09-18written 2026-10-18
What we still do not know
  • How big Oscar's 2026 risk-adjustment bill really is, which CMS settles only in its June 2027 report.
  • How many members CMS's eligibility checks remove by the end of 2026, and whether they cost more than the guide assumes.
  • How many members Oscar's employer-paid plans have; the company does not report the number.
The evidence under this - 4 claims
C08facthigh confidence
Risk-adjustment transfers paid out were $1,526.4M against $10,292.1M of direct premium in 2024 (14.8%), $2,596.8M against $14,031.3M in 2025 (18.5%), and $2,314.3M against $11,696.7M in the first half of 2026 (19.8%).
against this

The first-half figure includes about $160M of favourable 2025 true-up (C11); on current-year terms an analyst on the Q2 call estimated about 17.9%.

historical · FY2024 to H1 2026written 2026-10-18
C22facthigh confidence
The 10-Q says that as of 1 July 2026 about 250,000 to 300,000 members were expected to be retroactively disenrolled under CMS program integrity rules or fraud, waste and abuse law, and that premium for them is recorded as owed back to CMS rather than as revenue.
current state · 2026-07-01written 2026-10-18
C24management claimmedium confidence
The chief executive expects second-half membership churn about twice the 1% to 2% a month assumed earlier, as CMS eligibility removals delayed from Q2 arrive, and says the effects are in the guide. An analyst said CMS had sent insurers a list of 1 million members possibly unauthorised, about 80% in Florida and Texas; management gave no Oscar figure.
against this

The 10-Q states 250,000 to 300,000 expected removals (C22), but the CMS list Oscar is reviewing was not quantified for Oscar.

forwardwritten 2026-10-18
C43estimatelow confidence
Oscar's CHOICE members are probably in the tens of thousands, under 1% of its 2.96 million members, which is why the line is early.
against this

The share target is stated for its counties, not nationally, so the national figure could be lower or higher; Oscar has never stated the count.

current state · 2026-09-16written 2026-10-18

What would change our view

  1. Neutral→AttractiveThe price falls 20% under fair value

    It needs:

    • ○The share price falls to about $31.25, 80% of what we think the business is worth.about $31.26 today, 11% below the last close
  2. Neutral→UnattractiveThe price runs 20% above fair value

    It needs:

    • ○The share price rises to about $46.87, 20% above what we think the business is worth.about $47.16 today, 34% above the last close
  3. Neutral→UnattractiveThe payment to rivals rises again

    It needs any of:

    • ○The risk-adjustment payment rises above 21% of Oscar's direct premium for 2026.checked at the next results, due by 10 Feb
    • ○Oscar cuts its 2026 guide below $800M of profit from operations.checked at the next results, due by 10 Feb
We would also be wrong if
  • Retroactive removals run above 300,000 members, or members fall below 2.6 million by the end of 2026.
  • Oscar starts reporting its employer-paid members, and they pass 100,000 during 2027.

What is coming

  • 5 November 2026 Q3 2026 results: Whether the second half loses no more than the guide implies and how many members the eligibility checks removed.
Every dated event ahead
  • 5 November 2026 Q3 2026 results: Whether the second half loses no more than the guide implies and how many members the eligibility checks removed.
  • 15 January 2027 2027 open enrolment: Whether Oscar keeps growing in a market priced rationally, under mostly the old enrolment rules.
  • 15 February 2027 FY2026 results and 2027 guide: 2026's final risk-adjustment estimate, the 2027 margin guide and, perhaps, a CHOICE member count.
  • 30 June 2027 CMS risk adjustment report for 2026: The settled payment Oscar owes rivals for 2026, against its estimate of about 20% of direct premium.
Since we wrote this
Written
18 Oct
Price the thesis read
$31.89
16 Oct
Latest close
$35.19
close, · +10.3% since
  • 17 NovPrice moveHeld Neutral as the price touched our 80% lineThe price dipped to the edge of our 20% cushion and closed at about 80% of our value on no business news; three new directors joined the board. The view waits on the risk-adjustment payment.
  • 10 NovThesis reviewStill Attractive: priced at 78% of a value near $39.40Re-valued on the rules for cyclical margins and loss-history tax.
  • 10 NovPrice moveNeutral: priced at 82% of a value near $39.40The price crossed the 80% line of the base case; the business evidence did not move.
  • 9 NovThesis reviewAttractive: priced at 68% of a value near $44.85Re-valued in three stages at an 8% return, the method now drawn on every thesis: the price sits past the 20% margin of safety.
  • 6 NovEarningsOscar's call and 10-Q: the payment to rivals is near 17% of premium. View heldQ3 2026 results.
  • 5 NovEarningsQ3 operating profit $178M; 2026 forecast raised to $850M-$950MPart of the raise is a better estimate of what Oscar owes rivals, settled only in June 2027. The view stays Neutral until the payment share and removals are reported.
  • 5 NovBet moveBet re-struck: Priced for success to Safe, little upsideRe-priced at the 4 November close.
  • 4 NovBet moveBet re-struck: Safe, little upside to Priced for successRe-priced at the 3 November close.
  • 26 OctBet moveBet re-struck: Priced for success to Safe, little upsideRe-priced at the 23 October close.
  • 18 OctThesis writtenNeutral, medium convictionWritten after Investor Day raised the 2026 guide: a record year whose margin depends on a risk-adjustment bill CMS settles next June.

Also checked 1 time with nothing new to act on.

Sources 23

Where this came from

Sources - 23

Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.

  1. S01primarycompany filing2026-02-13
    Item 1, the risk factors, membership by state, the income statement, risk adjustment and the debt note
    backsC01C05C06C07C08C13C25C28C32C37C38C42C46C51C53
  2. S02primarycompany filing2026-08-07
    the balance sheet, statutory capital, membership, expected removals, the regulatory update, convertibles and share counts
    backsC03C04C08C11C21C22C23C26C27C28C29C44C47C49
  3. S03primarycompany release2026-08-06
    Q2 and first-half results and the August guide
    backsC02C03C13C46
  4. S04primarytranscript2026-08-06
    Oscar Health Q2 2026 earnings call transcript (FMP), held 6 August 2026
    risk adjustment, prior-period releases, churn, the CMS list, ICHRAx and Lucie
    So in general, we're a risk adjustment payer because our members skew younger.
    backsC04C10C11C12C17C24C41C52
  5. S05primarycompany release2026-09-16
    the raised 2026 guide, the 2029 targets, share and CHOICE slides, the 2024 targets
    Current 2029 projections assume: ~$20M in interest and other expenses, a mid-20s Effective Tax Rate, and 331M diluted shares as of 2Q26 growing 2-3% per year
    backsC12C13C14C15C17C18C21C31C32C39C43C44
  6. S06primarycompany release2026-09-16
    the 2029 margin, cost and share targets and the capital projection
    PROJECTED CUMULATIVE INTERNAL CAPITAL GENERATION, 2027 TO 2029
    backsC14C39C50
  7. S07primaryregulator2026-01-28
    national and state plan selections for 2026
    The Centers for Medicare & Medicaid Services (CMS) reports that 23.0 million consumers have signed up for 2026 individual market health insurance coverage through the Marketplaces
    backsC16C47
  8. S08primaryregulator2026-06-30
    each issuer's 2025 transfer, Oscar's three insurers and Florida Blue
    the absolute value of risk adjustment state transfers remained 11.0 percent of premiums in the individual non-catastrophic market risk pool
    backsC09
  9. S09primarycompany filing2026-02-17
    its exchange membership, the 2025 morbidity data, its 2026 repricing and segment revenue
    backsC07C19C21
  10. S10primarycompany filing2026-02-10
    its planned exchange retreat
    backsC20C21
  11. S11primarycompany filing2026-04-22
    ownership, pay and the leaders' records
    backsC33C34C45
  12. S12primarycompany filing2026-04-07
    the 1,000,000-share purchase from the company and the performance-share vesting
    backsC35
  13. S13primarycompany filing2026-08-31
    the option exercises and discretionary sales
    backsC36
  14. S14primarycompany filing2026-09-18
    the distribution in kind and Kushner's holding
    backsC37
  15. S15primaryvendor data2026-10-16
    Research pack for OSCR (FMP market tier, FINRA short interest, insider series), fetched 18 October 2026
    the 16 October close, ranges and returns, the trailing multiple, analysts, earnings reactions, short interest, the insider roster and headcount
    backsC30C31C36C46C55C56
  16. S16primaryindustry data2026-08-12
    the outside count of ICHRA lives and employers
    The data suggests the number of ICHRA-covered lives alone (not including the thousands of QSEHRA-covered lives) surpassed 500,000 at the beginning of 2026.
    backsC40C43
  17. S17primarycompany filing2026-02-06
    its Blue licence and business mix
    backsC48
  18. S18primarycompany release2026-02-10
    the first 2026 guide (profit from operations $250M to $450M) and the $475M revolving credit facility entered on 6 February 2026
    backsC12
  19. S19primarycompany release2026-11-05
    Q3 revenue, medical loss ratio, earnings from operations and net income, the $250M risk adjustment benefit and $42M of prior-period development, the raised 2026 guide, members at 30 September and the 30 September balance sheet
    backsC04C12C13C27C30C31C57C58
  20. S20secondaryvendor data2026-11-05
    FMP end-of-day close for OSCR via thesis_delta, read 2026-11-05
    content/OSCR/updates/2026-11-05-earnings.json
    the 2026-11-04 close of $35.19
    35.19 (2026-11-04)
    backsC30C31
  21. S21primarycompany filing2026-11-09
    trailing revenue, operating profit, stock pay, tax, debt, cash and the diluted share count
    backsC60
  22. S22secondaryvendor data2026-11-09
    the analysts' average revenue and operating profit for the next three fiscal years, and the close
    backsC59C60
  23. S23secondaryvendor data2026-11-10
    the 9 November 2026 close
    backsC60
Rendered from content/OSCR/thesis.json · thesis reviewed 2026-11-17. This page explains a company; it does not say what to pay, when to buy or how much.